Notice: This company has been marked as potentially delisted and may not be actively trading. NewLink Genetics (NLNK) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends NLNK vs. IRWD, SGMO, EBS, CDXS, RIGL, XOMA, VNDA, VSTM, LXRX, and ACHVShould you be buying NewLink Genetics stock or one of its competitors? The main competitors of NewLink Genetics include Ironwood Pharmaceuticals (IRWD), Sangamo Therapeutics (SGMO), Emergent BioSolutions (EBS), Codexis (CDXS), Rigel Pharmaceuticals (RIGL), XOMA (XOMA), Vanda Pharmaceuticals (VNDA), Verastem (VSTM), Lexicon Pharmaceuticals (LXRX), and Achieve Life Sciences (ACHV). These companies are all part of the "biotechnology" industry. NewLink Genetics vs. Ironwood Pharmaceuticals Sangamo Therapeutics Emergent BioSolutions Codexis Rigel Pharmaceuticals XOMA Vanda Pharmaceuticals Verastem Lexicon Pharmaceuticals Achieve Life Sciences Ironwood Pharmaceuticals (NASDAQ:IRWD) and NewLink Genetics (NASDAQ:NLNK) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, community ranking, risk, valuation, profitability, institutional ownership and earnings. Does the media refer more to IRWD or NLNK? In the previous week, Ironwood Pharmaceuticals had 7 more articles in the media than NewLink Genetics. MarketBeat recorded 7 mentions for Ironwood Pharmaceuticals and 0 mentions for NewLink Genetics. Ironwood Pharmaceuticals' average media sentiment score of 0.20 beat NewLink Genetics' score of 0.00 indicating that Ironwood Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Ironwood Pharmaceuticals Neutral NewLink Genetics Neutral Do analysts prefer IRWD or NLNK? Ironwood Pharmaceuticals currently has a consensus target price of $10.40, suggesting a potential upside of 133.71%. Given Ironwood Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Ironwood Pharmaceuticals is more favorable than NewLink Genetics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ironwood Pharmaceuticals 0 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50NewLink Genetics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more risk & volatility, IRWD or NLNK? Ironwood Pharmaceuticals has a beta of 0.41, meaning that its share price is 59% less volatile than the S&P 500. Comparatively, NewLink Genetics has a beta of 1.17, meaning that its share price is 17% more volatile than the S&P 500. Is IRWD or NLNK more profitable? Ironwood Pharmaceuticals has a net margin of -0.65% compared to NewLink Genetics' net margin of -4,592.84%. Ironwood Pharmaceuticals' return on equity of -0.96% beat NewLink Genetics' return on equity.Company Net Margins Return on Equity Return on Assets Ironwood Pharmaceuticals-0.65% -0.96% 0.74% NewLink Genetics -4,592.84%-41.50%-33.95% Do insiders & institutionals have more ownership in IRWD or NLNK? 32.3% of NewLink Genetics shares are owned by institutional investors. 12.9% of Ironwood Pharmaceuticals shares are owned by insiders. Comparatively, 12.7% of NewLink Genetics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has preferable earnings & valuation, IRWD or NLNK? NewLink Genetics has lower revenue, but higher earnings than Ironwood Pharmaceuticals. Ironwood Pharmaceuticals is trading at a lower price-to-earnings ratio than NewLink Genetics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIronwood Pharmaceuticals$378.42M1.88-$1.00B-$0.03-148.33NewLink Genetics$940K172.34-$42.99M-$1.03-4.21 Does the MarketBeat Community believe in IRWD or NLNK? Ironwood Pharmaceuticals received 125 more outperform votes than NewLink Genetics when rated by MarketBeat users. However, 71.56% of users gave NewLink Genetics an outperform vote while only 61.08% of users gave Ironwood Pharmaceuticals an outperform vote. CompanyUnderperformOutperformIronwood PharmaceuticalsOutperform Votes51061.08% Underperform Votes32538.92% NewLink GeneticsOutperform Votes38571.56% Underperform Votes15328.44% SummaryIronwood Pharmaceuticals beats NewLink Genetics on 12 of the 18 factors compared between the two stocks. Ad Crypto 101 MediaThe #1 Coin for November 2024Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this newly established trust, I believe this coin could skyrocket up to 150x+ in the next 30 days alone! I've compiled everything you need to know about this once-in-a-lifetime DeFi project into a brand-new comprehensive guide… You can get access to the report by clicking here now… Get NewLink Genetics News Delivered to You Automatically Sign up to receive the latest news and ratings for NLNK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NLNK vs. The Competition Export to ExcelMetricNewLink GeneticsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$162.00M$6.57B$5.14B$9.08BDividend YieldN/A2.99%5.09%4.23%P/E Ratio-3.7710.5990.1317.19Price / Sales172.34196.061,116.25117.05Price / CashN/A57.1643.1037.85Price / Book2.065.094.784.78Net Income-$42.99M$151.83M$120.31M$225.60M NewLink Genetics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NLNKNewLink GeneticsN/A$4.34flatN/AN/A$162.00M$940,000.00-3.7755IRWDIronwood Pharmaceuticals4.073 of 5 stars$3.46-2.0%$10.40+200.6%-59.9%$553.70M$442.73M-117.67220News CoverageSGMOSangamo Therapeutics1.7507 of 5 stars$2.56+24.6%$7.00+174.0%+537.4%$533.10M$176.23M-3.43480Analyst ForecastNews CoverageHigh Trading VolumeEBSEmergent BioSolutions4.0105 of 5 stars$8.92+5.2%$14.00+57.0%+253.7%$483.32M$1.09B-2.071,600Analyst DowngradeNews CoverageGap DownCDXSCodexis4.1525 of 5 stars$5.59+1.1%$8.33+49.1%+72.0%$454.90M$64.45M-6.36250Positive NewsRIGLRigel Pharmaceuticals3.3956 of 5 stars$19.15+1.3%$36.20+89.0%+35.6%$337.23M$116.88M135.08147Gap DownXOMAXOMA4.2711 of 5 stars$27.85+2.6%$81.50+192.6%+50.1%$328.07M$4.76M-7.8010News CoverageVNDAVanda Pharmaceuticals3.9361 of 5 stars$4.64+0.7%$15.50+234.1%+24.2%$270.55M$190.86M-16.54203Analyst ForecastNews CoverageVSTMVerastem3.786 of 5 stars$4.72+5.4%$12.50+164.8%-47.9%$210.07M$10M-1.4050Analyst ForecastNews CoverageLXRXLexicon Pharmaceuticals1.8046 of 5 stars$0.78-4.3%$6.00+673.5%-43.7%$191.01M$5.23M-1.08285News CoverageACHVAchieve Life Sciences2.0132 of 5 stars$4.16+1.5%$14.80+255.8%+6.6%$143.06MN/A-3.6320 Related Companies and Tools Related Companies Ironwood Pharmaceuticals Competitors Sangamo Therapeutics Competitors Emergent BioSolutions Competitors Codexis Competitors Rigel Pharmaceuticals Competitors XOMA Competitors Vanda Pharmaceuticals Competitors Verastem Competitors Lexicon Pharmaceuticals Competitors Achieve Life Sciences Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NLNK) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NewLink Genetics Corp Please log in to your account or sign up in order to add this asset to your watchlist. Share NewLink Genetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
